

## For Health Professionals Who Care for People with Cancer

### Inside This Issue

#### Editor's Choice

##### New Programs

**UGUAJNIV, UGUAJNIV4:** Adjuvant Treatment of Resected Urothelial Carcinoma using Nivolumab

**ULYZANU:** Treatment of Waldenström Macroglobulinemia using Zanubrutinib

**LYDHAPR:** Treatment of Lymphoma with Dexamethasone, Cytarabine, Platinum and ritUXimab

##### Revised Protocol and PPPO

**SCDRUGX:** Management of Infusion-Related Reactions to Systemic Therapy Agents

#### Drug Update

Romidepsin for Peripheral T-Cell Lymphoma

#### Provincial Systemic Therapy Policies

Policy V-10 : Hazardous Drugs Safe Handling

#### Cancer Drug Manual®

**New** Asciminib, Elrantamab **Revised** Nivolumab, Zanubrutinib Chemotherapy Preparation and Stability Chart

#### Chemotherapy Preparation and Stability Chart

**New** D-PACE, cisplatin, cyclophosphamide, etoposide

**Revised** Doxorubicin

#### BC Cancer Benefit Drug List

**New** UGUAJNIV, UGUAJNIV4, LYDHAPR, ULYZANU

**Revised** GOOVFNIRM, GOOVNIRAM, GUMCSPABI, GUMCSPAPA, GUMCSPENZ, HNAVPCPMB, HNAVPPMB, HNAVPMBF, HNAVPMBF6, LKMDSA, LKMSDL, LUAVENT, LUNETEV, LUNETEV, LYPRA, LYROMI

#### New Protocols, PPPOs and Patient Handouts

**BR** BRAVPTRAD, BRAVPTRAT, BRAVPTRVIN | **GU** UGUAJNIV, UGUAJNIV4 | **LY** LYDHAPR, ULYZANU **SC** SCDRUGRX

#### Revised Protocols, PPPOs and Patient Handouts

**BR** BRAJPEM, BRAVPTRAD, BRAVPTRAT, BRAVPTRVIN | **GI** GIBAJCAP, GICOXB, GIGAJCOX, GIGFLODOC, UGIPRRT, GIRCAP | **GO** ~~GOOVFNIRM~~, GOOVFNIRM, GOOVFNIRM, ~~GOOVNIRAM~~, GOOVNIRAM, GOOVNIRAM | **GU** GUAJPG, GUAJPG, GUAJPG, GUBAVE, ~~GUMCSPABI~~, ~~GUMCSPAPA~~, ~~GUMCSPENZ~~, GUNAJPG | **HN** ~~HNAVPCPMB~~, ~~HNAVPPMB~~, ~~HNAVPMBF~~, ~~HNAVPMBF6~~ | **LK** ~~LKMDSA~~, ~~LKMSDL~~, ULKMSDC | **LU** LUAJPC, LUAVCRZR, ~~LUAVENT~~, LUAVNP, LUAVPC, LUAVPCIPNI, LUAVPCPMB, LUAVPG, LUAVPGPMB, LUAVPP, LUAVPPIPNI, LUAVPPMB, LULACATRT, LULAPE2RT, LULAPERT, LUMMPG, LUMMPP, ~~LUNETEV~~, LUOTPE, LUOTPERT, LUPUPE, LUSCDURPE, LUSCPE, LUSCPERT, LUSCPI | **LY** LYEPOCHR, ~~LYPRA~~ | **SC** SCDRUGRX

#### Resources and Contact Information

### Editor's Choice

#### New Programs

BC Cancer Provincial Systemic Therapy has approved the following new treatment program effective 1 April 2023. Full details of all treatment programs are available in the [Chemotherapy Protocols](#) section of the BC Cancer website.

#### Genitourinary

**Adjuvant Treatment of Resected Urothelial Carcinoma using Nivolumab (UGUAJNIV, UGUAJNIV4)** — The BC Cancer Genitourinary Tumour Group is introducing adjuvant nivolumab treatment for patients with a high risk of recurrence of urothelial carcinoma after resection. The use of adjuvant nivolumab in this population is supported by the phase III CheckMate-274 trial. Compared to placebo, nivolumab showed a meaningful improvement in disease-free survival (20.8 mos vs. 10.8 mos, hazard ratio [HR] 0.70) as well as non-urothelial tract recurrence-free survival (22.9 mos vs. 13.7 mos, HR 0.72). The treatment was associated with manageable toxicities consistent with the known safety profile of nivolumab.<sup>1</sup>

## **Lymphoma**

**Treatment of Waldenström Macroglobulinemia using Zanubrutinib (ULYZANU)** — The BC Cancer Lymphoma Tumour Group is introducing zanubrutinib, an oral Bruton's tyrosine kinase (BTK) inhibitor, as a new option for patients with relapsed or refractory Waldenström macroglobulinemia and lymphoplasmacytic lymphoma. In an ongoing phase III (ASPEN) trial comparing zanubrutinib to ibrutinib, zanubrutinib was shown to have similar rates of complete response (CR) plus very good partial response (VGPR) (28.9% vs. 19.5%,  $p=0.116$ ), progression-free survival (18-month, 85% vs. 83.8%) and overall survival (18-month, 97% vs. 93.9%). Zanubrutinib was less toxic with lower rates of muscle spasms, peripheral edema, hypertension, and atrial fibrillation/atrial flutter, as well as similar infection rates despite of a higher rate of neutropenia (25% vs. 12%).<sup>2,3</sup>

**Treatment of Lymphoma with Dexamethasone, Cytarabine, Platinum and ritUXimab (LYDHAPR)** — The BC Cancer Lymphoma Tumour Group is introducing a new standard platinum-containing regimen for patients with relapsed or refractory aggressive lymphomas using rituximab, dexamethasone, cytarabine and cisplatin or carboplatin (R-DHAP). These include diffuse large B-cell lymphoma and mantle cell lymphoma. The R-DHAP regimen may be preferred over the current standard regimens of LYGDPR or LYRICE depending on prior treatments and comorbidities. Additionally, cytarabine is an active agent in mantle cell lymphoma, and R-DHAP may be used in patients who have exhausted all other options but who remain fit for a platinum-containing regimen. Compared to LYGDPR, the R-DHAP regimen has similar response rates, event-free survival and overall survival, with slightly more toxicities.<sup>14-713</sup>

Note that there are two particular toxicities associated with higher doses of cytarabine which have corresponding clinical assessment, actions, and patient teaching components:

- **Cerebellar toxicity:** assessment should be performed prior to each cytarabine dose. See protocol appendix for more information on performing these assessments and the assessment form.
- **Ocular toxicity:** corticosteroid eye drops should be prescribed and initiated immediately prior to receiving cytarabine. Patient teaching will be required as eye drop instillation will be continued by the patient at home every 6 hours as outlined in the protocol.

### **References**

1. Bajorin DF, et al. Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma. *N Engl J Med* 2021;384(22):2102-14.
2. Tam CS, et al. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: The ASPEN study. *Blood* 2020;136:2038–50.
3. Dimopoulos M, et al. Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: A substudy of the phase 3 ASPEN trial. *Blood Adv* 2020;4:6009-18.
4. Crump M, et al. Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12. *J Clin Oncol* 2014; 32:3490-97.
5. Gisselbrecht C, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. *J Clin Oncol* 2010;28 (27):4184-90.
6. Kanat O, et al. Modified outpatient dexamethasone, cytarabine and cisplatin regimen may lead to high response rates and low toxicity in lymphoma. *Med Princ Pract* 2010;19(5):344-7.
7. Olivieri A, et al. Salvage therapy with an outpatient DHAP schedule followed by PBSC transplantation in 79 lymphoma patients: an intention to mobilize and transplant analysis. *Eur J Hematol* 2004;72(1):10-7.

## REVISED Supportive Care Protocol and PPPO

### SCDRUGRX Protocol (Management of Infusion-Related Reactions to Systemic Therapy Agents)

The BC Cancer Provincial Systemic Therapy Program has updated the SCDRUGRX protocol and associated order sets. Highlights of the updates include:

- Protocol revisions focused around Subsequent Management After An Infusion-Related Reaction
- Minor revisions to PPPO-A: Immediate management of infusion-related reaction and resumption of infusion
- **\*NEW\*** Launch of provincial PPPO-B: Subsequent cycle infusion administration after infusion-related reaction

Teams should aim to transition their local/regional forms to the provincial version(s) within the month of April 2023.

For any questions or comments, approach your local regional systemic therapy leadership or the Provincial System Therapy team: [ProvincialSystemicOffice@bccancer.bc.ca](mailto:ProvincialSystemicOffice@bccancer.bc.ca)

## Drug Update

### Romimdepsin for Peripheral T-Cell Lymphoma

Romidepsin has been withdrawn by the manufacturer effective 20 March 2023 for new patients. The currently funded indication by BC Cancer (ULYROMI protocol) is for the Health Canada approved indication of treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL). Romidepsin has also been used for cutaneous T-cell lymphoma (CTLC) in BC as approved by the US Food and Drug Administration and this use is also affected by this withdrawal. For patients already on ULYROMI protocol, to continue treatment, physicians must enroll patients via the ISTODAX (romidepsin) Restricted Access Program ([https://istodaxhprc.ptm-health.com/ENG.aspx?cid=R6370E&wave\\_no=1](https://istodaxhprc.ptm-health.com/ENG.aspx?cid=R6370E&wave_no=1)).

The original approval of romidepsin for relapsed or refractory PTCL is based on the results of a phase II, open-label, single arm trial,<sup>1</sup> pending results from a phase III confirmatory study in patients with untreated PTCL. However, this phase III study has recently shown that the addition of romidepsin to standard CHOP chemotherapy regimen was not associated with improved progression-free survival compared to CHOP alone<sup>2</sup> and as a result PCTL indication was removed in the US in 2021 and more recently in Canada, with no new treatment started to be allowed.

For more information see, see Health Canada advisory on:

- [www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/notice-compliance/conditions/istodax-letter-health-professionals.html](http://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/notice-compliance/conditions/istodax-letter-health-professionals.html)

#### References

1. Coiffier B, Pro B, Prince HM, et al. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. *J Clin Oncol* 2012;30(6):631-6.
2. Bachy E, Camus V, Thieblemont C, et al. Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA). *J Clin Oncol*. 2022;40(3):242-251. doi:10.1200/JCO.21.01815

## Provincial Systemic Therapy Policies

**Policy V-10 : Hazardous Drugs Safe Handling** has been updated:

- Changes include significant simplification and removal of duplicating information. This was done with the goal of increasing the understanding of the document. It also resulted in a shorter policy.
- Additional links to governing and regulatory bodies have been added and imbedded into the policy for users ease and understanding.

## Cancer Drug Manual<sup>®</sup>

All documents are available in the [Cancer Drug Manual<sup>®</sup>](#) on the BC Cancer website.

### New Documents

Note that the following drug is not a BC Cancer Benefit Drug and requires application to the BC Cancer Compassionate Access Program (CAP). The corresponding Interim Monograph and Patient Handout are made available for reference only.

The **Asciminib Interim Monograph** and **Patient Handout** have been developed with expert review provided by Dr. Donna Forrest (medical oncologist, BC Cancer Leukemia Tumour Group) and Megan Darbyshire (tumour group pharmacist, BC Cancer Provincial Pharmacy). **Asciminib** is an allosteric tyrosine kinase inhibitor, specifically targeting the ABL myristoyl pocket (STAMP). Asciminib is used in the treatment of chronic myeloid leukemia. The usual dose is 80 mg orally once daily or 40 mg orally twice daily.

Highlights from these documents include:

- asciminib is associated with cardiovascular toxicity, hypertension, and arrhythmia including QTc prolongation
- use with caution in patients with a history of pancreatitis
- contraception is recommended for male and female patients of reproductive potential during treatment and for at least 1 week after the last dose
- absorption is decreased by food; administer on an empty stomach
- dispense in the original blister cards to protect from moisture

**Asciminib** has been added to the **Auxiliary Label List** and has been evaluated for the **BC Health Authorities Provincial Hazardous Drug List**.

The **Elranatamab Interim Monograph** has been developed. Elranatamab is a heterodimeric humanized (IgG2) bispecific antibody directed against B-cell maturation antigen (BCMA) and Cluster of differentiation 3 T-cell co-receptor (CD3). It is a T-cell directed therapy used in the treatment of multiple myeloma. Elranatamab is administered by subcutaneous injection in a 28 day cyclical regimen. Cycle 1 begins with two step-up priming doses (given on days 1 and 4), followed by the full dose administered on days 8, 15, and 22. For subsequent cycles, the full dose is administered on days 1, 8, 15, and 22. Outside of clinical trials, elranatamab is only available via the Health Canada Special Access Program.

## Cancer Drug Manual<sup>©</sup>

Highlights from this document include:

- premedication is required for both priming doses and the first full dose (cycle 1 days 1, 4, and 8) to mitigate cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS)
- closed system transfer devices (CSTDs) are acceptable to use for preparation, but they cannot be used for any period of storage of the prepared dose; prepared doses must be used immediately after preparation
- elranatmab is associated with impaired wound healing and bleeding which may be a risk following surgical procedures

Elranatmab has been added to the Chemotherapy Preparation and Stability Chart and has been evaluated for the BC Health Authorities Provincial Hazardous Drug List.

### Revised Documents

#### Nivolumab Monograph

*Uses:* added urothelial cancer

#### Zanubrutinib Monograph

*Dosage Guidelines:* added BC Cancer protocol (ULYZANU) and bolded/italicized BC Cancer usual dosing

#### Chemotherapy Preparation and Stability Chart

**D-PACE:** added instructions for a 3-in-1 solution of cisplatin, cyclophosphamide, and etoposide for protocol ULY0 D-PACE

**Doxorubicin:** added instructions for preparing bag for infusion for protocol ULY0 D-PACE

## BC Cancer Benefit Drug List

### New Programs

The following treatment programs have been added to the [Benefit Drug List](#) effective 01 April 2023:

Protocol Title	Protocol Code	Benefit Status
Adjuvant Treatment of Resected Urothelial Carcinoma using <b>Nivolumab</b>	UGUAJNIV	Restricted
Adjuvant Treatment of Resected Urothelial Carcinoma using 4-Weekly <b>Nivolumab</b>	UGUAJNIV4	Restricted
Treatment of Lymphoma with <b>Dexamethasone, Cytarabine, Platinum</b> and <b>riTUXimab</b>	LYDHAPR	Class I
Treatment of Waldenström Macroglobulinemia using <b>Zanubrutinib</b>	ULYZANU	Restricted

## Revised Programs

The following treatment programs have been added to the [Benefit Drug List](#) effective 01 April 2023:

Protocol Title	Protocol Code	Benefit Status
Maintenance Treatment of Newly Diagnosed Platinum Responsive Epithelial Ovarian Cancer using <b>Niraparib</b>	GOOVFNIRM	Class I <i>(previously Restricted)</i>
Maintenance Treatment of Relapsed Platinum Sensitive and Responsive Epithelial Ovarian Cancer using <b>Niraparib</b>	GOOVNIRAM	Class I <i>(previously Restricted)</i>
Therapy for Metastatic Castration Sensitive Prostate Cancer using <b>Abiraterone</b> and <b>predniSONE</b>	GUMCSPABI	Class I <i>(previously Restricted)</i>
Treatment of Metastatic Castration Sensitive Prostate Cancer using <b>Apalutamide</b>	GUMCSPAPA	Class I <i>(previously Restricted)</i>
Treatment for Metastatic Castration Sensitive Prostate Cancer using <b>Enzalutamide</b>	GUMCSPENZ	Class I <i>(previously Restricted)</i>
First-Line Treatment of Advanced Squamous Cell Carcinoma of the Head and Neck with <b>PACLitaxel, CARBOplatin</b> and <b>Pembrolizumab</b>	HNAVPCPMB	Class I <i>(previously Restricted)</i>
First-Line Treatment of Advanced Squamous Cell Carcinoma of the Head and Neck Using <b>Platinum, Fluorouracil</b> and <b>Pembrolizumab</b>	HNAVFPMB	Class I <i>(previously Restricted)</i>
First-Line Treatment of Advanced Squamous Cell Carcinoma of the Head and Neck with <b>Pembrolizumab</b>	HNAVPMBF	Class I <i>(previously Restricted)</i>
First-Line Treatment of Advanced Squamous Cell Carcinoma of the Head and Neck using 6-Weekly <b>Pembrolizumab</b>	HNAVPMBF6	Class I <i>(previously Restricted)</i>
Therapy of Myelodysplastic Syndrome and Acute Myeloid Leukemia using <b>azaCITIDine</b>	LKMDSA	Class I <i>(previously Restricted)</i>
Therapy of Myelodysplastic Syndrome using <b>Lenalidomide</b>	LKMDSL	Class I <i>(previously Restricted)</i>
First-Line Treatment of ROS1-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) with <b>Entrectinib</b>	LUAVENT	Class I <i>(previously Restricted)</i>
Treatment of Advanced Neuroendocrine Tumours of Lung Origin (Non-Functional) Using <b>Everolimus</b>	LUNETEV	Class I <i>(previously Restricted)</i>
Treatment of Advanced Neuroendocrine Tumours of Lung Origin (Non-Functional) Using <b>Everolimus</b>	LUNETEV	Class I <i>(previously Restricted)</i>
Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) with <b>Pralatrexate</b>	LYPRA	Class I <i>(previously Restricted)</i>

## New & Revised Protocols, PPPOs and Patient Handouts

BC Cancer Protocol Summaries, Provincial Pre-Printed Orders (PPPOs) and Patient Handouts are revised periodically. New, revised or deleted protocols, PPPOs and patient handouts for this month are listed below, with document revisions indicated in the respective columns. Protocol codes for treatment requiring BC Cancer Compassionate Access Program (CAP) approval are prefixed with the letter **U**.

### NEW Protocols, PPPOs and Patient Handouts (*new documents checked* )

Protocol Code	Protocol Title	Protocol	PPPO	Handout
<b>BRAVPTRAD</b>	Palliative Therapy for Metastatic Breast Cancer using PERTuzumab, Trastuzumab, and DOCETaxel as First-Line Treatment for Advanced Breast Cancer	-	-	<input checked="" type="checkbox"/>
<b>BRAVPTRAT</b>	Palliative Therapy for Metastatic Breast Cancer using PERTuzumab, Trastuzumab, and PACLitaxel as First-Line Treatment for Advanced Breast Cancer	-	-	<input checked="" type="checkbox"/>
<b>BRAVPTRVIN</b>	Palliative Therapy for Metastatic Breast Cancer using PERTuzumab, Trastuzumab, and Vinorelbine as First-Line Treatment for Advanced Breast Cancer	-	-	<input checked="" type="checkbox"/>
<b>UGUAJNIV</b>	Adjuvant Treatment of Resected Urothelial Carcinoma using Nivolumab	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
<b>UGUAJNIV4</b>	Adjuvant Treatment of Resected Urothelial Carcinoma using 4-Weekly Nivolumab	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
<b>LYDHAPR</b>	Treatment of Lymphoma with Dexamethasone, Cytarabine, Platinum and riTUXimab	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	-
<b>ULYZANU</b>	Treatment of Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma using Zanubrutinib	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
<b>SCDRUGRX</b>	Management of infusion-related reactions to systemic therapy agents	-	PPPO-B <input checked="" type="checkbox"/>	-

## REVISED Protocols, PPOs and Patient Handouts (*revisions in respective columns*)

Protocol Code	Protocol Title	Protocol	PPO	Handout
<b>BR   Breast</b>				
<b>BRAJPEM</b>	Adjuvant Treatment of Resected Triple Negative Breast Cancer using Pembrolizumab	<i>Eligibility clarified</i>	--	--
<b>BRAVPTRAD</b>	Palliative Therapy for Metastatic Breast Cancer using PERTuzumab, Trastuzumab, and DOCEtaxel as First-Line Treatment for Advanced Breast Cancer	--	<i>Pretreatment metrics revised</i>	--
<b>BRAVPTRAT</b>	Palliative Therapy for Metastatic Breast Cancer using PERTuzumab, Trastuzumab, and PACLitaxel as First-Line Treatment for Advanced Breast Cancer	--	<i>Pretreatment metrics revised</i>	--
<b>BRAVPTRVIN</b>	Palliative Therapy for Metastatic Breast Cancer using PERTuzumab, Trastuzumab, and Vinorelbine as First-Line Treatment for Advanced Breast Cancer	--	<i>Pretreatment metrics revised</i>	--
<b>GI   Gastrointestinal</b>				
<b>GIBAJCAP</b>	Adjuvant Therapy of Biliary Cancer using Capecitabine	<i>Eligibility clarified</i>	--	--
<b>GICOXB</b>	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer using Oxaliplatin, Bevacizumab and Capecitabine	--	<i>Premedications clarified</i>	--
<b>GIGAJCOX</b>	Adjuvant Chemotherapy in Gastric Cancer Patients with D2 Resection (Node Negative) or Ineligible for Adjuvant Chemoradiation using Oxaliplatin and Capecitabine	--	<i>Premedications clarified</i>	--
<b>GIGFLODOC</b>	Perioperative Treatment of Resectable Adenocarcinoma of the Stomach, Gastroesophageal Junction or Lower 1/3 Esophagus using DOCEtaxel, Oxaliplatin, Infusional Fluorouracil, and Leucovorin	--	<i>Premedications clarified</i>	--
<b>UGIPRRT</b>	Peptide Receptor Radionuclide Therapy (PRRT) using Lutetium <sup>177</sup> Lu-Dotatate (LUTATHERA) for Treatment in Patients with Somatostatin Receptor Positive Midgut Neuroendocrine Tumours	<i>Referral process updated</i>	--	--
<b>GIRCAP</b>	Adjuvant Therapy for Stage II and III Rectal Cancer using Capecitabine in Patients Previously Treated with Preoperative Radiation Therapy Alone <del>using Capecitabine</del>	<i>Title updated, eligibility clarified, exclusions added</i>	--	<i>Title updated, side effects updated</i>
<b>GO   Gynecologic</b>				
<b>GOOVFNIRM</b>	Maintenance Treatment of Newly Diagnosed Platinum Responsive Epithelial Ovarian Cancer using Niraparib	<i>Protocol code revised, CAP requirement deleted</i>	<i>Protocol code revised, CAP requirement deleted</i>	--
<b>GOOVFOLAM</b>	Maintenance Treatment of Newly Diagnosed BRCA-Mutated Platinum Responsive Epithelial Ovarian Cancer using Olaparib	<i>Eligibility updated</i>	--	--



## REVISED Protocols, PPOs and Patient Handouts *(revisions in respective columns)*

Protocol Code	Protocol Title	Protocol	PPPO	Handout
<b>UGOONIRAM</b>	Maintenance Treatment of Relapsed Platinum Sensitive and Responsive Epithelial Ovarian Cancer using Niraparib	<i>Protocol code revised, CAP requirement deleted</i>	<i>Protocol code revised, CAP requirement deleted</i>	--
<b>GOVOLAPM</b>	Maintenance Treatment of Relapsed, BRCA-Mutated, Platinum Sensitive and Responsive Epithelial Ovarian Cancer using Olaparib	<i>Eligibility updated</i>	--	--
<b>GU   Genitourinary</b>				
<b>GUAJPG</b>	Neo-Adjuvant Therapy for Urothelial Carcinoma Using Cisplatin and Gemcitabine	<i>Eligibility and exclusions revised</i>	<i>Premedications updated</i>	--
<b>GUAVEV</b>	Palliative Therapy for Urothelial Carcinoma using Enfortumab Vedotin	<i>Eligibility revised</i>	--	--
<b>GUAVPG</b>	Palliative Therapy for Urothelial Carcinoma Using Cisplatin and Gemcitabine	<i>Eligibility and exclusions clarified</i>	<i>Premedications updated</i>	--
<b>GUBAVE</b>	Maintenance Therapy of Locally Advanced or Metastatic Urothelial Carcinoma using Avelumab	<i>Exclusions revised, contact physician phone numbers corrected</i>	--	--
<b>UGUMCSPABI</b>	Metastatic Castration Sensitive Prostate Cancer using Abiraterone and predniSONE	<i>Protocol code revised, CAP requirement deleted, eligibility clarified</i>	<i>Protocol code revised, CAP requirement deleted</i>	<i>Protocol code revised, CAP requirement deleted</i>
<b>UGUMCSPAPA</b>	Metastatic Castration Sensitive Prostate Cancer using Apalutamide	<i>Protocol code revised, CAP requirement deleted, eligibility clarified</i>	<i>Protocol code revised, CAP requirement deleted</i>	--
<b>UGUMCSPENZ</b>	Metastatic Castration Sensitive Prostate Cancer using Enzalutamide	<i>Protocol code revised, CAP requirement deleted, eligibility clarified</i>	<i>Protocol code revised, CAP requirement deleted</i>	--
<b>GUNAJPG</b>	Neo-Adjuvant Therapy for Urothelial Carcinoma Using Cisplatin and Gemcitabine	<i>Eligibility and exclusions clarified, premedications and precautions updated</i>	<i>Premedications updated</i>	--
<b>HN   Head &amp; Neck</b>				
<b>UHNAVCPMB</b>	First-Line Treatment of Advanced Squamous Cell Carcinoma of the Head and Neck with PAclitaxel, CARBOplatin and Pembrolizumab	<i>Protocol code revised, CAP requirement deleted</i>	<i>Protocol code revised, CAP requirement deleted</i>	<i>Protocol code revised, CAP requirement deleted</i>

## REVISED Protocols, PPPOs and Patient Handouts *(revisions in respective columns)*

Protocol Code	Protocol Title	Protocol	PPPO	Handout
<b>UHNVPFMB</b>	First-Line Treatment of Advanced Squamous Cell Carcinoma of the Head and Neck Using Platinum, Fluorouracil and Pembrolizumab	<i>Protocol code revised, CAP requirement deleted</i>	<i>Protocol code revised, CAP requirement deleted</i>	<i>Protocol code revised, CAP requirement deleted</i>
<b>UHNVPMBF</b>	First-Line Treatment of Advanced Squamous Cell Carcinoma of the Head and Neck with Pembrolizumab	<i>Protocol code revised, CAP requirement deleted</i>	<i>Protocol code revised, CAP requirement deleted</i>	<i>Protocol code revised, CAP requirement deleted</i>
<b>UHNVPMBF6</b>	First-Line Treatment of Advanced Squamous Cell Carcinoma of the Head and Neck using 6-Weekly Pembrolizumab	<i>Protocol code revised, CAP requirement deleted</i>	<i>Protocol code revised, CAP requirement deleted</i>	<i>Protocol code revised, CAP requirement deleted</i>
<b>LK   Leukemia</b>				
<b>ULKMSA</b>	Therapy of Myelodysplastic Syndrome and Acute Myeloid Leukemia using azaCITIDine	<i>Protocol code revised, CAP requirement deleted, eligibility clarified</i>	<i>Protocol code revised, CAP requirement deleted</i>	--
<b>ULKMSDC</b>	Therapy of Myelodysplastic Syndrome using Decitabine-Cedazuridine	<i>Eligibility and exclusions updated</i>	--	--
<b>ULKMSL</b>	Therapy of Myelodysplastic Syndrome using Lenalidomide	<i>Protocol code revised, CAP requirement deleted, Dose modifications clarified</i>	<i>Protocol code revised, CAP requirement deleted</i>	--
<b>LU   Lung</b>				
<b>LUAJPC</b>	Adjuvant CARBOplatin and PACLitaxel Following Resection of Stage I, II and IIIA Non-small Cell Lung Cancer	--	<i>Premedications updated</i>	--
<b>LUAVCRIZR</b>	First-Line Treatment of ROS1-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) with Crizotinib	<i>Eligibility updated</i>	--	--
<b>LUVAVENT</b>	First-Line Treatment of ROS1-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) with Entrectinib	<i>Protocol code revised, CAP requirement deleted</i>	<i>Protocol code revised, CAP requirement deleted</i>	--
<b>LUAVNP</b>	Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) with CISplatin and Vinorelbine	<i>Premedications updated, cisplatin bag size clarified</i>	<i>Premedications updated</i>	--
<b>LUAVPC</b>	First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with CARBOplatin and PACLitaxel	--	<i>Premedications updated</i>	--

## REVISED Protocols, PPOs and Patient Handouts *(revisions in respective columns)*

Protocol Code	Protocol Title	Protocol	PPO	Handout
LUAVPCIPNI	First-Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer with PACLitaxel, CARBOplatin, Ipilimumab and Nivolumab	<i>Antiemetics updated</i>	<i>Cycles 1 and 2 ppo: premedications updated</i>	--
LUAVPCPMB	First-Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer with PACLitaxel, CARBOplatin and Pembrolizumab	<i>Antiemetics updated</i>	<i>Premedications updated</i>	--
LUAVPG	Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with Platinum and Gemcitabine	--	<i>Premedications updated</i>	--
LUAVPGPMB	First-Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer with Platinum, Gemcitabine and Pembrolizumab	--	<i>Premedications updated</i>	--
LUAVPP	First-Line Treatment of Advanced Non-Small Cell Lung Cancer with Platinum and Pemetrexed	--	<i>Premedications updated</i>	--
LUAVPPIPNI	First-Line Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer with Platinum, Pemetrexed, Ipilimumab and Nivolumab	--	<i>Cycles 1 and 2 PPO: premedications updated</i>	--
LUAVPPPMB	First-Line Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer with Platinum, Pemetrexed and Pembrolizumab	--	<i>Premedications updated</i>	--
LULACATRT	Treatment of Locally Advanced Non-Small Cell Lung Cancer using CARBOplatin and PACLitaxel with Radiation Therapy	<i>Antiemetics updated</i>	<i>Premedications updated</i>	--
LULAPE2RT	Treatment of Locally Advanced Non-Small Cell Lung Cancer Using Alternative Dosing of CISplatin and Etoposide with Radiation Therapy	<i>Premedications updated</i>	<i>Premedications updated</i>	--
LULAPERT	Treatment of Locally Advanced Non-Small Cell Lung Cancer using CISplatin and Etoposide with Radiation Therapy	<i>Premedications updated, cisplatin bag size clarified</i>	<i>Premedications updated</i>	--
LUMMPG	Treatment of Malignant Mesothelioma with Platinum and Gemcitabine	--	<i>Premedications updated</i>	--
LUMMPP	Treatment of Malignant Mesothelioma with Platinum and Pemetrexed	--	<i>Premedications updated</i>	--
 LUNETEV	Treatment of Advanced Neuroendocrine Tumours of Lung Origin (Non-Functional) Using Everolimus	<i>Protocol code revised, CAP requirement deleted</i>	<i>Protocol code revised, CAP requirement deleted</i>	--
LUOTPE	Treatment of Thymoma with CISplatin and Etoposide	<i>Premedications updated, cisplatin bag size clarified</i>	<i>Premedications updated</i>	--
LUOTPERT	Treatment of Thymoma Using CISplatin and Etoposide with Radiation Therapy	<i>Premedications updated, cisplatin bag size clarified</i>	<i>Premedications updated</i>	--

## REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Protocol Code	Protocol Title	Protocol	PPPO	Handout
LUPUPE	Treatment of Cancer of Unknown Primary Involving the Thorax with CISplatin and Etoposide	<i>Premedications updated, cisplatin bag size clarified</i>	<i>Premedications updated</i>	--
LUSCDURPE	Treatment of Extensive Stage Small Cell Lung Cancer (SCLC) with Durvalumab, Platinum and Etoposide	<i>Premedications updated, precautions revised</i>	<i>Premedications updated</i>	--
LUSCPE	Treatment of Extensive Stage Small Cell Lung Cancer (SCLC) with <b>Platinum</b> and Etoposide	<i>Title and eligibility clarified, premedications updated, dose modifications and precautions revised</i>	<i>Pretreatment metrics and premedications updated</i>	<i>Side effects updated</i>
LUSCPERT	Treatment of Limited Stage Small Cell Lung Cancer using <b>Platinum</b> and Etoposide with Radiation Therapy	<i>Title clarified, premedications updated, cisplatin bag size clarified, dose modifications and precautions revised</i>	<i>Pretreatment metrics and premedications updated</i>	<i>Side effects updated</i>
LUSCPI	Second-Line Treatment of Extensive Stage Small Cell Lung Cancer (SCLC) with Irinotecan With or Without Platinum	<i>Premedications updated</i>	<i>Premedications updated</i>	--
<b>LY   Lymphoma</b>				
LYEPOCHR	Treatment of Lymphoma with Dose-Adjusted Etoposide, DOXOrubicin, vinCRISline, Cyclophosphamide, predniSONE and riTUXimab with Intrathecal Methotrexate	<i>Mesna recommendations revised</i>	--	--
LYPRA	Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) with Pralatrexate	<i>Protocol code revised, CAP requirement deleted, eligibility clarified</i>	<i>Protocol code revised, CAP requirement deleted</i>	<i>Protocol code revised, CAP requirement deleted</i>
<b>SC   Supportive Care</b>				
LYEPOCHR	Treatment of Lymphoma with Dose-Adjusted Etoposide, DOXOrubicin, vinCRISline, Cyclophosphamide, predniSONE and riTUXimab with Intrathecal Methotrexate	<i>Mesna recommendations revised</i>	--	--
SCDRUGRX	Management of infusion-related reactions to systemic therapy agents	<i>Subsequent Management section updated</i>	<i>Minor revision on Immediate management and resumption of infusion of PPPO-A</i>	--

## Resources and Contact Information

Resource	Phone	Email / Toll Free / Fax
Systemic Therapy Update: <a href="http://www.bccancer.bc.ca/health-professionals/clinical-resources/systemic-therapy/systemic-therapy-update">www.bccancer.bc.ca/health-professionals/clinical-resources/systemic-therapy/systemic-therapy-update</a>		
CST Bulletin: <a href="http://www.bccancer.bc.ca/health-professionals/clinical-resources/systemic-therapy/cst-bulletin">http://www.bccancer.bc.ca/health-professionals/clinical-resources/systemic-therapy/cst-bulletin</a>		
Systemic Therapy Update Editor	604-877-6000 x 672649	<a href="mailto:bulletin@bccancer.bc.ca">bulletin@bccancer.bc.ca</a>
Oncology Drug Information	604-877-6275	<a href="mailto:druginfo@bccancer.bc.ca">druginfo@bccancer.bc.ca</a>
Cancer Drug Manual Editor	250-519-5500 x 693742	<a href="mailto:nbadry@bccancer.bc.ca">nbadry@bccancer.bc.ca</a>
Pharmacy Oncology Certification	250-712-3900 x 686820	<a href="mailto:rxchemocert@bccancer.bc.ca">rxchemocert@bccancer.bc.ca</a>
Nurse Educators	604-877-6000 x 672638	<a href="mailto:nursinged@bccancer.bc.ca">nursinged@bccancer.bc.ca</a>
CAP – Compassionate Access Program	604-877-6277	<a href="mailto:cap_bcca@bccancer.bc.ca">cap_bcca@bccancer.bc.ca</a> fax 604-708-2026
OSCAR – Online System for Cancer Drugs Adjudication and Reimbursement	888-355-0355	<a href="mailto:oscar@bccancer.bc.ca">oscar@bccancer.bc.ca</a> fax 604-708-2051
Manufacturer Patient Assistance Programs: <a href="http://www.bccancer.bc.ca/mpap">http://www.bccancer.bc.ca/mpap</a>		
Library/Cancer Information	604-675-8003	<a href="mailto:requests@bccancer.bc.ca">requests@bccancer.bc.ca</a> toll free 888-675-8001 x 8003
Library Document Delivery	604-675-8002	<a href="mailto:requests@bccancer.bc.ca">requests@bccancer.bc.ca</a>
Pharmacy Professional Practice	604-877-6000 x 672247	<a href="mailto:mclin@bccancer.bc.ca">mclin@bccancer.bc.ca</a>
Professional Practice, Nursing	604-877-6000 x 672623	<a href="mailto:BCcancerPPNAdmin@ehcnet.phsa.ca">BCcancerPPNAdmin@ehcnet.phsa.ca</a>
Provincial Systemic Therapy	604-877-6000 x 672247	<a href="mailto:mclin@bccancer.bc.ca">mclin@bccancer.bc.ca</a>
BC Cancer – Abbotsford	604-851-4710	toll free 877-547-3777
BC Cancer – Kelowna	250-712-3900	toll free 888-563-7773
BC Cancer – Prince George	250-645-7300	toll free 855-775-7300
BC Cancer – Surrey	604-930-2098	toll free 800-523-2885
BC Cancer – Vancouver	604-877-6000	toll free 800-663-3333
BC Cancer – Victoria	250-519-5500	toll free 800-670-3322
Community Oncology Network (CON) sites: To update your contact information, please contact: <a href="mailto:bulletin@bccancer.bc.ca">bulletin@bccancer.bc.ca</a>		

## Editorial Review Board

Mario de Lemos, PharmD, MSc(Oncol) (Acting Editor)  
 Fatima Ladha, BScPharm, PharmD (Assistant Editor)  
 Jeevan Dosanjh, RN, BScN

Alina Gerrie, MD, MPH, FRCPC  
 Samuel Hackett, RN, BScN, CON(C)  
 Alison Pow, BScPharm